Dataset Information

Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthma.

ABSTRACT:

Aim

To present the methods and outcomes of stakeholder engagement in the development of interventions for children presenting to the emergency department (ED) for uncontrolled asthma.

Methods

We engaged stakeholders (caregivers, physicians, nurses, administrators) from six EDs in a three-phase process to: define design requirements; prototype and refine; and evaluate.

Results

Interviews among 28 stakeholders yielded themes regarding in-home asthma management practices and ED discharge experiences. Quantitative and qualitative evaluation showed strong preference for the new discharge tool over current tools.

Conclusion

Engaging end-users in contextual inquiry resulted in CAPE (CHICAGO Action Plan after ED discharge), a new stakeholder-balanced discharge tool, which is being tested in a multicenter comparative effectiveness trial.

SUBMITTER: Erwin K

PROVIDER: S-EPMC4900169 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthma.

Erwin Kim K Martin Molly A MA Flippin Tara T Norell Sarah S Shadlyn Ariana A Yang Jie J Falco Paula P Rivera Jaime J Ignoffo Stacy S Kumar Rajesh R Margellos-Anast Helen H McDermott Michael M McMahon Kate K Mosnaim Giselle G Nyenhuis Sharmilee M SM Press Valerie G VG Ramsay Jessica E JE Soyemi Kenneth K Thompson Trevonne M TM Krishnan Jerry A JA

Journal of comparative effectiveness research 20151221 1

<h4>Aim</h4>To present the methods and outcomes of stakeholder engagement in the development of interventions for children presenting to the emergency department (ED) for uncontrolled asthma.<h4>Methods</h4>We engaged stakeholders (caregivers, physicians, nurses, administrators) from six EDs in a three-phase process to: define design requirements; prototype and refine; and evaluate.<h4>Results</h4>Interviews among 28 stakeholders yielded themes regarding in-home asthma management practices and E ...[more]

PMID: 26690579

Similar Datasets

Project description:BackgroundFor children who have uncontrolled asthma despite the use of low-dose inhaled corticosteroids (ICS), evidence to guide step-up therapy is lacking.MethodsWe randomly assigned 182 children (6 to 17 years of age), who had uncontrolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinded step-up therapies in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up). We used a triple-crossover design and a composite of three outcomes (exacerbations, asthma-control days, and the forced expiratory volume in 1 second) to determine whether the frequency of a differential response to the step-up regimens was more than 25%.ResultsA differential response occurred in 161 of 165 patients who were evaluated (P<0.001). The response to LABA step-up therapy was most likely to be the best response, as compared with responses to LTRA step-up (relative probability, 1.6; 95% confidence interval [CI], 1.1 to 2.3; P=0.004) and ICS step-up (relative probability, 1.7; 95% CI, 1.2 to 2.4; P=0.002). Higher scores on the Asthma Control Test before randomization (indicating better control at baseline) predicted a better response to LABA step-up (P=0.009). White race predicted a better response to LABA step-up, whereas black patients were least likely to have a best response to LTRA step-up (P=0.005).ConclusionsNearly all the children had a differential response to each step-up therapy. LABA step-up was significantly more likely to provide the best response than either ICS or LTRA step-up. However, many children had a best response to ICS or LTRA step-up therapy, highlighting the need to regularly monitor and appropriately adjust each child's asthma therapy. (ClinicalTrials.gov number, NCT00395304.)

Dataset Information

Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthma.

Aim

Methods

Results

Conclusion

Publications

Engaging stakeholders to design a comparative effectiveness trial in children with uncontrolled asthma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets